A classical selection of men at risk of prostate cancer (PCa) is achieved by the determination of serum prostate-specific antigen (PSA), digital rectal examination (DRE), and the recent incorporation of multiparametric magnetic resonance imaging (mpMRI) to combine systematic ultrasound (US)-guided biopsies with targeted biopsies [1]. This evidence concerns the gene KLK3 and prostate cancer.